Kinase and IAP Inhibitor Combination Therapy for Proliferative Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a substantial unmet medical need for more effective treatments for various diseases, particularly in combination therapies that leverage inhibitors of cellular kinases and Inhibitors of Apoptosis (IAPs).

Innovation Solution

A combination therapy comprising inhibitors of cellular kinases and IAPs, utilizing compounds of formula I with a bivalent linker, is used to treat diseases effectively.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If combination therapy with inhibitors of cellular kinases and IAPs is used, then treatment effectiveness is improved, but treatment complexity increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines two separate therapeutic agents (inhibitor of cellular kinases and inhibitor of IAPs) into a single combination therapy regimen. This merging of multiple treatment mechanisms targets both proliferative and anti-apoptotic pathways simultaneously, thereby improving overall treatment effectiveness for cancers and pulmonary diseases while managing the complexity through coordinated administration protocols

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If combination therapy with multiple inhibitors is implemented, then disease treatment efficacy is enhanced, but the number of therapeutic agents increases

Engineering Contradiction:

Improvedisease treatment efficacyVSAvoidnumber of therapeutic agents

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The invention employs a combination therapy approach that integrates two specific therapeutic agents: an inhibitor of cellular kinases (such as ponatinib) and an inhibitor of IAPs (such as birinapant). This targeted combination enhances disease treatment efficacy by simultaneously blocking proliferation signals and preventing anti-apoptotic mechanisms, while the quantity of agents is optimized to the minimum effective combination rather than using broader polypharmacy approaches

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20260060957A1Compounds and compositions useful for treatment of proliferative disease or disorder

Publication Date: 2026.03.05 TRACT PHARMACEUTICALS INC

AI summary

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof and methods of using the same.